CorMedix Inc. to Present at the Cantor Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Pharmaceutical
ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight
As the stage is set for another year of groundbreaking research and transformative treatment advancements, several companies are seizing the...
Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform
Cellares and Sony will collaborate on integrating Sony's cell sorting and analytical technologies into the Cell Shuttle, Cellares' automated cell...
PhaseV Unveils Machine Learning-Powered Platform to Improve Oncology Clinical Trials
Company Leverages Causal Machine Learning to Overcome Key Challenges in Developing New Cancer Treatments BOSTON, Sept. 12, 2024 /PRNewswire/ --...
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
CAMBRIDGE, England, Sept. 12, 2024 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring...
Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion App to aid in the treatment of Parkinson’s Disease
STOCKHOLM, Sept. 12, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to...
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all...
Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
$10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract...
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind...
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x higher.Noom stands...
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed...
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ Meeting
NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”),...
PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV
MINNEAPOLIS, MN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics...
PetMed Express, Inc. Announces Appointment of Robyn D’Elia as Chief Financial Officer
D’Elia Brings More than 25 Years of Strategic Finance and Retail Leadership Experience to PetMedsDELRAY BEACH, Fla., Sept. 12, 2024...
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...